Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Barinthus Biotherapeutics (BRNS) EBITDA Margin (2020 - 2025)

Historic EBITDA Margin for Barinthus Biotherapeutics (BRNS) over the last 6 years, with Q2 2025 value amounting to 1283600.0%.

  • Barinthus Biotherapeutics' EBITDA Margin changed N/A to 1283600.0% in Q2 2025 from the same period last year, while for Sep 2025 it was 24060.25%, marking a year-over-year decrease of 237775900.0%. This contributed to the annual value of 425.76% for FY2024, which is 74665100.0% up from last year.
  • Latest data reveals that Barinthus Biotherapeutics reported EBITDA Margin of 1283600.0% as of Q2 2025.
  • Barinthus Biotherapeutics' 5-year EBITDA Margin high stood at 1666800.0% for Q4 2021, and its period low was 1283600.0% during Q2 2025.
  • For the 5-year period, Barinthus Biotherapeutics' EBITDA Margin averaged around 22289.29%, with its median value being 2870.7% (2021).
  • In the last 5 years, Barinthus Biotherapeutics' EBITDA Margin soared by 2000000000bps in 2021 and then tumbled by 2000000000bps in 2022.
  • Barinthus Biotherapeutics' EBITDA Margin (Quarter) stood at 1666800.0% in 2021, then plummeted by -100bps to 388.62% in 2022, then plummeted by -1304bps to 5455.09% in 2023, then surged by 100bps to 7.13% in 2024, then crashed by -18007793bps to 1283600.0% in 2025.
  • Its EBITDA Margin stands at 1283600.0% for Q2 2025, versus 4750.63% for Q1 2025 and 7.13% for Q3 2024.